Lubrano Ennio, Spadaro Antonio
Dipartimento di Scienze per la Salute, Università del Molise, Campobasso, Italy.
Acta Biomed. 2011 Apr;82(1):26-34.
The treatment of Rheumatoid Arthritis (RA) has changed since the introduction of biological agents. In particular, the anti Tumor Necrosis Factor (TNF)-alpha molecules have been the first group of drugs showing a good efficacy and safety profile. Among these, a new anti TNF-alpha antibody has been recently indicated for the treatment of RA: certolizumab pegol (CZP). In the main clinical trials this new pegylated anti TNF-alpha has shown to be efficacious on clinical, functional and prevention of structural damage in patients with active RA and with inadequate response to traditional disease modifying drugs, including methotrexate. Moreover CZP showed to be well tolerated and most adverse events occurred were mild or moderate. Therefore, results obtained showed that this new molecule can play a role in the treatment of RA.
自从生物制剂问世以来，类风湿关节炎（RA）的治疗发生了变化。特别是，抗肿瘤坏死因子（TNF）-α分子是首批显示出良好疗效和安全性的药物。其中，一种新型抗TNF-α抗体最近被批准用于治疗RA：赛妥珠单抗聚乙二醇化（CZP）。在主要临床试验中，这种新型聚乙二醇化抗TNF-α已显示出对活动性RA且对包括甲氨蝶呤在内的传统疾病改善药物反应不足的患者在临床、功能和预防结构损伤方面有效。此外，CZP耐受性良好，大多数不良事件为轻度或中度。因此，所获得的结果表明，这种新分子可在RA治疗中发挥作用。
